Articles tagged with Somatostatin
The European Society of Endocrinology has released the EndoCompass Research Roadmap, a major new initiative to align research efforts and improve funding strategies for hormone-related health challenges. The roadmap identifies specific research needs across eight endocrine specialties and five cross-cutting areas.
Researchers discovered a new pathway that could help people with diabetes avoid dangerous hypoglycemia by restoring the function of delta cells. These cells, previously unknown to play a role in blood sugar regulation, release somatostatin to pause insulin production when necessary.
A new study reveals the complex brain circuits involved in growth hormone release during sleep. The findings provide a map for understanding how sleep and hormone regulation interact, potentially leading to new treatments for sleep disorders and degenerative diseases.
Dr. Reichlin's groundbreaking work on brain-hormone interactions and his influence on generations of endocrinologists are being celebrated through a Festschrift series in Brain Medicine. The series explores multiple facets of his contributions, including pioneering work on hypothalamic control of pituitary function and early recognitio...
Researchers at University of Gothenburg propose inhibiting somatostatin to restore glucagon release and prevent dangerous blood sugar levels. This approach has the potential to save lives and is supported by experimental results in mice with type 1 diabetes.
A deadly marine cone snail's venom contains a toxin that interacts with human cells in a specific manner, regulating blood sugar levels and hormone balance. This discovery may lead to the design of more effective drugs for treating diabetes and endocrine disorders.
Researchers at IISc have developed a novel method to improve pharmacokinetic properties of macrocyclic peptides, which are used in pharmaceutical industries worldwide. By substituting oxygen with sulphur in the backbone of these peptides, they increase resistance to digestive enzymes and lipophilicity, thereby boosting bioavailability.
Researchers discuss lurbinectedin as a method to treat neuroendocrine tumors (NETs), with encouraging results from phase II basket studies demonstrating activity in platinum-sensitive relapsed SCLC and other malignancies. Lurbinectedin's mechanism of action involves inhibiting oncogenic transcription, promoting apoptosis and cell death.
Researchers at Helmholtz-Zentrum Dresden-Rossendorf developed a new strategy to increase target molecules for radionuclide therapy in pheochromocytoma tumors, delaying tumor growth. The combination of valproic acid and decitabine prior to therapy doubled the radiation dose absorbed by the tumor.
Studies on prion diseases in mice reveal coordinated gene expression changes before symptoms appear, shedding light on selective vulnerability and potential treatment targets. Researchers predict disease progression using new methods, suggesting therapies may be more effective when applied early.
A University of Ottawa research team has made new discoveries on how motor skills are learned and stored in the brain. By studying mice, they found that a specific transcription factor called NPAS4 regulates gene changes in inhibitory neurons, leading to the formation of learning-associated neuron ensembles.
A KAIST research team has discovered a new role for somatostatin, a protein-based neurotransmitter, in reducing the toxicity caused by Alzheimers disease. When somatostatin is met with copper and Aβ proteins, it attenuates the toxicity and agglomeration of metal-Aβ complexes.
A new study from the University of Copenhagen suggests that the poison from the sea snail species Conus rolani can function as a painkiller, blocking out pain in mice for an even longer time than morphine. This discovery offers a potential alternative to addictive painkillers like morphine and opioids.
Researchers discovered a new venom compound in deep-water cone snails, similar to the hormone somatostatin, with possible pharmaceutical applications for treating chronic pain and other human maladies. The study highlights the rich biochemical diversity of animal venoms and the need to explore new compounds.
Researchers at Shinshu University discovered a new type of amyloidosis associated with duodenal neuroendocrine tumors that produce somatostatin. Laser microdissection and liquid chromatography-tandem mass spectrometry techniques were used to identify the amyloid formation.
Researchers found that somatostatin interneurons can cause seizures when they go haywire, disrupting the brain's balance. The study identified a rare epilepsy syndrome and developed mouse models to understand the neurological dysfunction, paving the way for new treatments.
Researchers at Uppsala University have designed new antibodies that bind to both large and small aggregates of the amyloid-beta protein, potentially providing a more effective treatment for Alzheimer's disease. The new antibody format is stronger in binding to clumps and can also target smaller aggregates.
A new treatment method increases the body's own degradation of protein building blocks, reducing all types of aggregates. The method uses somatostatin fused to a brain transport protein, allowing it to enter the brain and target the smallest, most toxic aggregates.
Researchers found that somatostatin neurons, involved in emotional processing and addiction, are impacted by alcohol withdrawal. Targeting these neurons may be a viable candidate for treating depression related to alcohol withdrawal.
Researchers at KAIST found that neuropeptide somatostatin improves visual processing and cognitive functions by reducing excitatory inputs to parvalbumin-positive interneurons. The study provides a new insight into the therapeutics of neurodegenerative diseases, particularly Alzheimer's disease.
The NETTER-2 study is a Phase III clinical trial evaluating Lutathera's efficacy and safety in treating Grade 2 and 3 advanced GEP-NETs. The primary objective is to prolong Progression Free Survival in patients with high proliferation rate tumors.
A new long-lasting type of radionuclide therapy has been proven effective in treating advanced neuroendocrine tumors, with the treatment lasting up to 4 times longer than previous options. The therapy, Lutathera-177 (Lu-DOTA-EB-TATE), was well-tolerated and showed promising results in a Phase I trial.
In a phase 3 study, Lutathera treatment results in improved progression-free survival and higher objective radiographic response rates compared to Octreotide LAR. The safety profile of Lutathera was also favorable with low-grade adverse events.
Researchers at McLean Hospital discovered that individuals with bipolar disorder have altered somatostatin expression in the brain's amygdala, which regulates anxiety and stress response. This altered circadian function is linked to severity of depression and anxiety symptoms, providing potential neural correlates for circadian rhythm ...
Researchers found that somatostatin neurons temporarily cloak synapses in the neocortex, silencing neighboring excitatory neurons and altering brain circuit structure. This discovery could dramatically change how we understand and use the connectome.
An international research team has shown that an investigational agent that sticks onto the surface of tumor cells can effectively image tumors. The 'antagonist', 111In-DOTA-BASS, outperformed the widely used 'agonist' agent, OctreoScan, in detecting neuroendocrine tumors.
A case of false positive octreoscan in Crohn's disease was reported in the World Journal of Gastroenterology, highlighting a potential misdiagnosis. The study found that immunohistochemical studies did not reveal somatostatin receptors in the sample, and no explanation for the abnormal uptake was determined.
Recent research suggests that gastrin inhibits cell apoptosis in colorectal cancer by up-regulating FasL expression, allowing cancer cells to evade immune surveillance. Somatostatin promotes cell apoptosis in large intestine cancer by increasing caspase-3 levels and activating death receptor signaling pathways.
Researchers at Salk Institute and collaborators found that antagonists, not agonists, are more effective in targeting tumors. Antagonists can bind to a greater variety of receptor conformations, making them a more efficient target.